Reference:	FOI.4563.20	
Subject:	Prescribing in growth hormone and acromegaly	
Date of Request:	20 November 2020	

Requested:

- 1. How many patients has your trust treated in the last 12 months with the following drugs?
 - Octreotide
 - Lanreotide
 - Pasireotide
 - Pegvisomant
 - Genotropin
 - Humatrope
 - Norditropin
 - Nutropin
 - Omnitrope
 - Saizen
 - Zomacton
- 2. Please provide the number of patients under the age 16 that were treated in the last 12 months with each of the following drugs:
 - Genotropin
 - Humatrope
 - Norditropin
 - Nutropin
 - Omnitrope
 - Saizen
 - Zomacton
- 3. How many patients have been treated in the last 12 months with the following drugs for Acromegaly (ICD10 code E22.0) ONLY?
 - Sandostatin LAR
 - Octreotide Long-Acting (Generic)
 - Somatuline Autogel
 - Pasireotide

Response:

1. Hywel Dda University Health Board (UHB) provides, within the table below, the number patients treated with the listed medications, during the last twelve (12) months, as requested.

Medication	Number of patients
Octreotide	57
Lanreotide	11
Pasireotide	0
Pegvisoman	0
Genotropin	Section 40 -

	Full exemption below
Humatrope	0
Norditropin	9
Nutropin	0
Omnitrope	Section 40 -
	Full exemption below
Saizen	0
Zomacton	0

2. The UHB is unable to provide you with the exact number of patients due to the low numbers of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the Data Protection Act 2018/ General Data Protection Regulations 2016 (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/General Data Protection Regulations 2016 defines personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.

3. The UHB confirms that no patients have been treated with the listed medications for Acromegaly (ICD10 code E22.0) only, during the in the last twelve (12) months.